Cartesian Therapeutics reported a third quarter 2026 net loss of $11.5 million, significantly narrower than the prior year and outperforming analyst loss estimates. The company is transitioning into a late-stage clinical organization with its lead candidate, Descartes-08, currently in a Phase 3 trial for myasthenia gravis (MG) and multiple Phase 2 trials for other autoimmune conditions.
Key Highlights
- Phase 3 AURORA trial data for Descartes-08 in MG is expected in the first quarter of 2027, with a BLA filing planned for mid-2027.
- Cash and equivalents totaled $124.7 million as of September 30, 2026, which the company expects will support operations into 2028.
- Recent retreatment data for Descartes-08 showed a mean 6.6-point MG-ADL reduction at Month 12 with no new safety signals observed.
- R&D expenses increased to $15.6 million from $13.8 million year-over-year, primarily due to higher Phase 3 clinical trial and manufacturing costs.